CN111995585A - Pyrimidine acetamides and their use as inhibitors of phosphodiesterase PDE2 activity - Google Patents
Pyrimidine acetamides and their use as inhibitors of phosphodiesterase PDE2 activity Download PDFInfo
- Publication number
- CN111995585A CN111995585A CN202010771191.7A CN202010771191A CN111995585A CN 111995585 A CN111995585 A CN 111995585A CN 202010771191 A CN202010771191 A CN 202010771191A CN 111995585 A CN111995585 A CN 111995585A
- Authority
- CN
- China
- Prior art keywords
- pde2
- oxo
- acetamide
- methyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 title claims abstract description 53
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 title claims abstract description 53
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 title claims abstract description 53
- 230000000694 effects Effects 0.000 title claims abstract description 23
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title claims abstract description 16
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title claims abstract description 16
- 239000003112 inhibitor Substances 0.000 title claims abstract description 8
- CXRXPRDOJLWWPV-UHFFFAOYSA-N CC(N)=O.C1=CN=CN=C1 Chemical class CC(N)=O.C1=CN=CN=C1 CXRXPRDOJLWWPV-UHFFFAOYSA-N 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- -1 pyrimidine acetamide compound Chemical class 0.000 claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 239000002243 precursor Substances 0.000 claims abstract description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 208000015114 central nervous system disease Diseases 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- UNVSUFWPBRZLPE-UHFFFAOYSA-N propan-2-yl 4-[[2-[[5-(2-hydroxyethyl)-6-methyl-4-oxo-1h-pyrimidin-2-yl]sulfanyl]acetyl]amino]benzoate Chemical compound C1=CC(C(=O)OC(C)C)=CC=C1NC(=O)CSC1=NC(=O)C(CCO)=C(C)N1 UNVSUFWPBRZLPE-UHFFFAOYSA-N 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 239000003889 eye drop Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000003387 muscular Effects 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 20
- 102000004190 Enzymes Human genes 0.000 abstract description 14
- 108090000790 Enzymes Proteins 0.000 abstract description 14
- 230000002255 enzymatic effect Effects 0.000 abstract description 14
- 230000005764 inhibitory process Effects 0.000 abstract description 10
- 239000004480 active ingredient Substances 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 16
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000027455 binding Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 4
- 229940121828 Phosphodiesterase 2 inhibitor Drugs 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000003032 molecular docking Methods 0.000 description 4
- MYTWFJKBZGMYCS-NQIIRXRSSA-N bay 60-7550 Chemical compound C1=C(OC)C(OC)=CC=C1CC(NN12)=NC(=O)C1=C(C)N=C2[C@H]([C@@H](C)O)CCCC1=CC=CC=C1 MYTWFJKBZGMYCS-NQIIRXRSSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- 238000003041 virtual screening Methods 0.000 description 3
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 101100135858 Caenorhabditis elegans pde-2 gene Proteins 0.000 description 2
- 208000020358 Learning disease Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000009149 molecular binding Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 1
- 101150042997 21 gene Proteins 0.000 description 1
- IOSAAWHGJUZBOG-UHFFFAOYSA-N 3-(6-amino-9h-purin-9-yl)nonan-2-ol Chemical compound N1=CN=C2N(C(C(C)O)CCCCCC)C=NC2=C1N IOSAAWHGJUZBOG-UHFFFAOYSA-N 0.000 description 1
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100024316 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Human genes 0.000 description 1
- 102100024318 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B Human genes 0.000 description 1
- 102100024317 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C Human genes 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 101001098814 Dictyostelium discoideum 3',5'-cyclic-nucleotide phosphodiesterase regA Proteins 0.000 description 1
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LCSHXRUETFCYNN-UHFFFAOYSA-N FC1=CC=C(C=C1)NC(CSC=1NC(C(=C(N1)C)C=CO)=O)=O.C(C)(=O)N Chemical compound FC1=CC=C(C=C1)NC(CSC=1NC(C(=C(N1)C)C=CO)=O)=O.C(C)(=O)N LCSHXRUETFCYNN-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001117044 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Proteins 0.000 description 1
- 101001117099 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B Proteins 0.000 description 1
- 101001117094 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C Proteins 0.000 description 1
- 101000701876 Homo sapiens Serpin A9 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000050111 human SERPINA9 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly discloses a pyrimidine acetamide compound and application thereof as a phosphodiesterase PDE2 activity inhibitor. At least one of pyrimidine acetamide compounds or hydrates, pharmaceutically acceptable salts, tautomers, stereoisomers and precursor compounds thereof is used as an active ingredient for preparing a medicament for preventing or treating PDE2 disorder. The pyrimidine acetamide compound can effectively inhibit the activity of PDE2 enzymekit and PDE-GloTMPhosphodiesterase Assay for determining the enzymatic level IC50Has good PDE2 enzyme inhibition effect. The compound of the invention is used as an effective inhibitor of PDE2, is expected to be used as an active ingredient for preparing a medicament for treating PDE2 disorder, and has medicinal prospect.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly discloses a pyrimidine acetamide compound and application thereof as a phosphodiesterase PDE2 activity inhibitor.
Background
Adenosine cyclophosphate (Cyclic adenosine 3 ', 5' monophosphosphate, cAMP) was first discovered by all and Sutherland et al in 1958; guanosine monophosphate (cGMP) was discovered by Ashman et al in 1963. Since then, studies on cyclic adenosine monophosphate and cyclic guanosine monophosphate have received increasing attention.
Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) regulate gene expression in cells by means of controlling ion channels, are important second messengers in cells and are involved in the realization of numerous physiological functions, such as learning memory, cell cycle regulation, cell differentiation, proliferation, inflammatory processes, smooth muscle contraction relaxation, visual signal transduction, and metabolic functions, such as steroid synthesis, insulin secretion, glycogen synthesis, lipogenesis, etc.
Intracellular levels of cAMP and cGMP are controlled by the corresponding cyclases and Phosphodiesterases (PDEs) to maintain their concentrations within an optimal range for responding to a signal. Adenylate cyclase and guanylate cyclase respectively catalyze ATP and GTP in vivo to be converted into cAMP and cGMP, and the concentration of a second messenger is increased; while PDEs are the only family of enzymes in the body that can hydrolyze cAMP and cGMP to the inactive substances 5 '-AMP and 5' -GMP, reducing the intracellular concentration of the second messenger. Therefore, PDE can be used as target of action of various disease drugs, and the effect of disease treatment is achieved by blocking hydrolysis process of PDE on cAMP/cGMP, maintaining intracellular concentration of second messenger, and reversing reduction of concentration in the disease process.
Cyclic nucleoside phosphodiesterases contain at least 11 structurally related but functionally distinct gene families (PDE1-PDE 11). High levels of PDE will result in the induction of visual deterioration, congestive heart failure, depression, asthma, erectile dysfunction and inflammation. Selective PDE inhibitors play an important role in inhibiting platelet aggregation, treating depression, parkinson's disease and learning disorders. Each family has 21 gene products with different isoforms and splice variants, and encodes these 11 PDE protein families. Examples of the PDE1 include PDE1A, PDE1B, PDE1C and the like.
PDE2(Phosphodiesterase2) is a member of the PDEs isozyme family, has only one subtype (PDE2A), is a homodimer structure, and has a dual action of hydrolyzing cAMP and cGMP simultaneously. PDE2 is mainly distributed in the central nervous system of human body and is expressed more in cortex of brain and hippocampus, and studies have shown that PDE2 can be involved in the regulation of central nervous system diseases, and corresponding PDE2 inhibitors have been shown to treat central nervous system diseases related to depression, anxiety and learning and memory disorders. The PDE2 inhibitor can improve mild cognitive impairment and age-related memory disorder diseases by inhibiting PDE2 protein activity to increase cAMP and cGMP levels, and inhibit thrombosis, and can be used for treating cancer, dementia and blood disorders. The existing PDE2 inhibitors are mainly EHNA, BAY60-7750, dipyridamole and the like, but are not yet on the market. It would therefore be desirable to find novel PDE2 inhibitors that would aid in later drug development.
Disclosure of Invention
The present invention provides compounds of formula I, and methods of using these compounds to treat PDE2 disorders by inhibiting PDE 2.
The present invention provides compounds of formula I and their docking forms, chelates, non-covalent complexes, prodrugs, stereoisomers, solvates, pharmaceutically acceptable salts and mixtures thereof.
X is NH-R1。
R1Selected from hydrogen, alkyl, aryl, heteroaryl, -C (═ O) -alkyl, -C (═ O) -aryl, or-C (═ O) -heteroaryl, any of which may optionally be substituted with one or more independent Q1Substituted by groups;
Q1selected from hydrogen, halogen, -CN, -CF3,-OCF3,-NO2Oxy, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, heterocycloaryl, -OR2,-S(O)nR3,-NR4R5,-SO2NR4R5,-C(O)R6,-C(O)NR4R5,-C(O)OR7,-OC(O)R8,-NR4C(O)R6,-NR4S(O)2R9,-NR10C(O)NR4R5,-NR10S(O)2NR4R5or-NR10S(O)NR4R5Any of the foregoing groups may optionally be substituted with one or more independent hydrogen, halogen, -CN, -OH, -NH2,-NO2Oxy, -CF3,-OCF3,-CO2H,-S(O)nH, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, heteroaryl or-O-alkyl, any of which may be partially or fully halogenated;
n is 0, 1, or 2.
Further, the compound is 4- {2- [5- (2-Hydroxy-ethyl) -4-methyl-6-oxo-1,6-dihydro-pyrimidin-2-ylsulfanyl ] -acetylamino } -benzoic acid isopropyl ester (4- {2- [5- (2-Hydroxy-ethyl) -4-methyl-6-oxo-1,6-dihydro-pyrimidin-2-ylsulfanyl ] -acetylamino } -benzoic acid isopropyl ester) having the formula,
n- (3-Ethynyl-5,6-dihydro-4H-cyclopenta [ b ] thiophen-2-yl) -2- [5- (2-hydroxy-ethyl) -4-methyl-6-oxo-1, 6-dihydropyrimidin-2-ylsulfanyl ] -acetamide (N- (3-ethyl-5, 6-dihydro-4H-cyclopenta [ b ] thiophen-2-yl) -2- [5- (2-
n- (4-fluorophenyl) -2- ((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide (N- (4-fluorophenyl) -2- ((5- (2-hydroxyethenyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide), which has the structural formula,
n-benzyl-2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide (N-benzyl-2- ((5- (2-hydroxyethyi) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide), which has the structural formula
2- ((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) -N- (4-methoxybenzyl) acetamide (2- ((5- (2-hydroxyethyi) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) -N- (4-methoxybenzyl) acetamide), the structural formula of which is shown in the specification
N-butyl-2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide
(N-butyl-2- ((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide), the structural formula of which is shown in the specification
2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) -N- (1,3,4-thiadiazol-2-yl) acetamide
(2- ((5- (2-hydroxyethenyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) -N- (1,3,4-thiadiazol-2-yl) acetamide), the structural formula of which is shown in the specification
The invention also provides a novel use of a compound of formula I for the manufacture of a medicament for the treatment of a PDE2 disorder, wherein the PDE2 disorder is a central nervous system disorder. Central nervous system disorders are: psychiatric disorders and conditions; anxiety disorders; movement disorders; a substance-related disorder; mood disorders; neurodegenerative disorders; pain; autistic disorder.
The invention also provides a medicament prepared from the compound of the formula I, a hydrate, a pharmaceutically acceptable salt, a tautomer, a stereoisomer or a precursor compound thereof and one or more pharmaceutically acceptable carriers.
Wherein the carrier comprises diluent, excipient, filler, binder, humectant, disintegrant, absorption enhancer, surfactant, adsorption carrier, lubricant, etc. conventional in pharmaceutical field.
The medicine can be made into various forms such as injection, tablet, powder, granule, pill, capsule, oral liquid, ointment, cream, etc. The medicaments in various dosage forms can be prepared according to the conventional method in the pharmaceutical field.
The medicine is used for treating PDE2 disorder by inhibiting phosphodiesterase PDE2 activity, and can be introduced into body such as muscle, intradermal, subcutaneous, intravenous, and mucosal tissue by injection, spray, nasal drop, eye drop, penetration, absorption, physical or chemical mediated method; or mixed or coated with other materials and introduced into body.
Searching and finding out that the compound of formula I can inhibit the activity of PDE2 enzyme from SPECS library by adopting a method integrating virtual screening and experimental determination, carrying out advanced evaluation on the effectiveness of drug molecules by adopting a computer simulation method, detecting and verifying the activity by adopting a biological experimental method, obtaining a series of effective PDE2 enzyme inhibitors, and carrying out virtual screening and experimental determination on the inhibitorscAMP kit and PDE-GloTMPhosphodiesterase Assay for determining the enzymatic level IC50The series of compounds have good PDE2 enzyme inhibition effect, and the researches are very important for finally developing anti-PDE 2 medicaments and have important application prospects.
Drawings
FIG. 1 is a drawing ofcAMP kit assay of the Compound 4- {2- [5- (2-hydroxy-ethyl) -4-methyl-6-oxo-1,6-dihydro-pyrimidin-2-ylsulfanyl]-a graph of IC50 values of isopropyl acetylamino } -benzoate at the PDE2 protein level;
FIG. 2 is PDE-GloTMPhosphodiesterase Assay of the Compound 4- {2- [5- (2-hydroxy-ethyl) -4-methyl-6-oxo-1,6-dihydro-pyrimidin-2-ylsulfanyl]-a graph of IC50 values of isopropyl acetylamino } -benzoate at the PDE2 protein level;
FIG. 3 is PDE-GloTMPhosphodienesterase Assay of N- (3-ethynyl-5,6-dihydro-4H-cyclopenta [ b ] b]Thien-2-yl) -2- [5- (2-hydroxy-ethyl) -4-methyl-6-oxo-1, 6-dihydropyrimidin-2-ylsulfanyl]IC of acetamide at the PDE2 protein level50A graph of values;
FIG. 4 is a drawing showingAMP kit was assayed for the compound N- (4-fluorophenyl) -2- ((5- (2-hydroxyethyl) -4)-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide IC50 value profile at PDE2 protein level;
FIG. 5 is PDE-GloTMA graph of the IC50 value of compound N- (4-fluorophenyl) -2- ((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide at the PDE2 protein level, as measured by Phosphodiesterase Assay;
FIG. 6 is a drawing showingA graph of the IC50 value of the compound N-benzyl-2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide at the PDE2 protein level as measured by AMP kit;
FIG. 7 is PDE-GloTMA graph of the IC50 value of the compound N-benzyl-2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide at the PDE2 protein level, as measured by Phosphodiesterase Assay;
FIG. 8 is a drawing showingA graph of the IC50 value of the compound 2- ((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) -N- (4-methoxybenzyl) acetamide at the PDE2 protein level as determined by AMP kit;
FIG. 9 is PDE-GloTMA graph of the IC50 value of the compound 2- ((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) -N- (4-methoxybenzyl) acetamide at the PDE2 protein level as measured by Phosphodiesterase Assay;
FIG. 10 is PDE-GloTMA graph of the IC50 value of the compound N-butyl-2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide at the PDE2 protein level, as measured by Phosphodiesterase Assay;
FIG. 11 is a schematic view ofAMP kit measured the compound 2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) -N- (1,3,4-thiadiazol-2-yl) acetamide IC50 value map at PDE2 protein level;
FIG. 12 is PDE-GloTMA graph of the IC50 value of the compound 2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) -N- (1,3,4-thiadiazol-2-yl) acetamide at the PDE2 protein level was determined by Phosphodiesterase Assay.
Detailed Description
The present invention is further described below with reference to examples, but is not limited thereto.
1. Experimental methods
1.1 virtual receptor-based screening
First adoptThe Protein Preparation module in the software package was used to manipulate the crystal structure of PDE2 (PDB: 4 HTX). The library of SPECS compounds (http:// www.specs.net /) was pretreated with ligaprep for compounds including removal of heavies, salt ions and minerals, possible ionization states and tautomers of the compounds at pH 7.4, and ring conformations, etc.
Before virtual screening by adopting a molecular docking method, the effectiveness of the adopted Glide docking method needs to be verified, a PDE2 active site is defined, and the center of mass of ligand molecules BAY60-7550 in a crystal structure is set as the centerIn the cube region, the ligand molecule BAY60-7550 was treated with LigPrep in the same manner as in SP (Standard precision) parameter setting of Glide software, and then docked into the active pocket of PDE2 again, and Glide was found to better reproduce the binding conformation in the crystal structure.
The SPECS library compounds were docked and scored using the Glide SP (Standard Precision) mode, retaining the 3 ten thousand small molecule binding mode that precedes the score. In the crystal structure of the binding of BAY60-7550 to PDE2, hydrogen bond interactions with the active region residue GLN859 and pi-pi interactions with PHE862 are formed. For 3 ten thousand small molecule binding modes generated by docking, hydrogen bond standards are adopted as screening conditions, binding modes which form more than 1 hydrogen bond with GLN859 are selected, and 3660 qualified binding modes are obtained. In order to fully consider the structural diversity of the compounds, a Canvas module in Schrodinger is adopted for carrying out cluster analysis, reasonable binding modes are manually selected, 48 compounds are finally obtained, Shanghai ceramic company is entrusted as a proxy to purchase compound entities from SPECS company, and experimental determination is carried out. The compound with the structure shown in the formula I is found to have better PDE2 enzyme inhibition activity.
1.2 PDE2 in vitro enzyme Activity detection assay procedure
1) Expression and purification of PDE2 protein: pET15b-PDE2A (580-941) wild-type and truncated plasmids were awarded by the professor Cazechun university, North Ka, USA. After sequencing, the cells were transformed into E.coli BL21+ (Codon Plus) and induced to express (after induction with 0.1mM IPTG, incubation was continued at 15 ℃ for 20 hours), and then purified by Ni column to obtain His-tagged PDE2 protein.
2) PDE2 in vitro enzyme activity detection procedure:
add 4 μ LPDE2 protein and 2 μ L candidate compound (7 concentrations per compound, 3 parallel experiments) and incubate for 30 min;
then adding 4. mu.L Bio-cAMP to react with the residual PDE2 protein in the previous step for 1 hour;
adding 15 mu L of mixed solution of Donor Bead and Acceptor in a dark environment for reaction for 1 hour;
and reading the signal value of the micropore plate by using a multifunctional microplate reader.
Each group of experiments is provided with a positive maximum value control and a negative minimum value control, only a Bio-cAMP substrate is added without adding protein to be used as the positive control, and the substrate is the most at the moment, the signal value is the largest, and the control can be also called as a full inhibition control; protein and Bio-cAMP substrates were added as negative controls, protein was all involved in hydrolysis, and excess substrate gave the signal when the signal value was minimal, also referred to as the perhydrolysis control. Each of the above experiments was performed in 3 parallel experiments, each step requiring centrifugation (rotation speed 1000r/min, centrifugation for 1 minute).
② use of PDE-GloTMPhosphodiesterase Assay compounds were tested for their inhibitory effect on PDE 2:
mu.L of the compound to be screened (7 concentrations of each compound determined, 3 parallel experiments) and 1.5. mu.L of PDE2 were added to each well and incubated for 30 minutes at room temperature;
2.5. mu.L of 2. mu.M cAMP was added and incubated at room temperature for 20 minutes;
add 2.5. mu.L PDE-Glo per wellTMTermination Buffer,2.5μL PDE-GloTMDetection Solution, incubation for 20 minutes at room temperature;
finally adding 10 μ L of a solution containingOf substratesBuffer, incubation for 10 minutes at room temperature;
and reading the signal value of the micropore plate by using a multifunctional microplate reader.
Negative and positive controls were set for each set of experiments, negative controls: cAMP and no PDE protein were added. The highest cAMP content, highest PKA activity, and most ATP consumed by phosphorylated substrates, and therefore the weakest luminescent signal, is obtained with the lowest plate reading value without addition of PDE protein. Positive control: cAMP and PDE proteins were added. PDE hydrolyzes most of cAMP, PKA activity is reduced, ATP consumed by phosphorylated substrates is reduced, remaining ATP is increased, and luminescence signal is strongest, which is the set of the maximum plate reading value.
Example 1
With 4- {2- [5- (2-hydroxy-ethyl) -4-methyl-6-oxo-1,6-dihydro-pyrimidin-2-ylsulfanyl]-acetylamino } -benzoic acid isopropyl ester (SPECS library number: AS-871/43478043) viaAMP kit for detecting its enzymatic level IC50The value was 57.75. + -. 6.91. mu. mol/L (as shown in FIG. 1), which was in turn determined by PDE-GloTMPhosphodiesterase Assay for determining the enzymatic level IC50The value is 16.29 +/-0.35 mu mol/L (shown in figure 2), and the PDE2 enzyme inhibition effect is good;
example 2
Using N- (3-ethynyl-5,6-dihydro-4H-cyclopenta [ b ]]Thien-2-yl) -2- [5- (2-hydroxy-ethyl) -4-methyl-6-oxo-1, 6-dihydropyrimidin-2-ylsulfanyl]Acetamide (SPECS library number: AS-871/43478035) via PDE-GloTMPhosphodiesterase Assay for determining the enzymatic level IC50The value is 1.652 +/-0.352 mu mol/L (shown in figure 3), and the product has good PDE2 enzyme inhibition effect.
Example 3
N- (4-fluorophenyl) -2- ((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide viaAMP kit for detecting its enzymatic level IC50The value was 16.905. + -. 2.155. mu. mol/L (as shown in FIG. 4), which was in turn PDE-GloTMPhosphodiesterase Assay for determining the enzymatic level IC50The value was 6.068. + -. 0.872. mu. mol/L (as shown in FIG. 5), which was excellent in PDE2 enzyme inhibition effect.
Example 4
N-benzyl-2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide viaAMP kit for detecting its enzymatic level IC50The value was 34.67. + -. 4.58. mu. mol/L (as shown in FIG. 6), which was in turn PDE-GloTMPhosphodiesterase Assay for determining the enzymatic level IC50The value is 24.615 +/-3.705 mu mol/L (shown in figure 7), and the PDE2 enzyme inhibition effect is good.
Example 5
2- ((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) -N- (4-methoxybenzyl) acetamide viaAMP kit for detecting its enzymatic level IC50The value was 22.21. + -. 2.3. mu. mol/L (as shown in FIG. 8), which was in turn determined by PDE-GloTMPhosphodiesterase Assay for its enzymatic level IC50The value was 17.08. + -. 1.4. mu. mol/L (as shown in FIG. 9), which was excellent in PDE2 enzyme inhibitory effect.
Example 6
N-butyl-2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide via PDE-GloTMPhosphodiesterase Assay for determining the enzymatic level IC50The value was 38.79 + -6.17. mu. mol/L (as shown in FIG. 10), which showed good PDE2 enzyme inhibition effect.
Example 7
2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) -N- (1,3,4-thiadiazol-2-yl) acetamide viaAMP kit for detecting its enzymatic level IC50The value was 16.53. + -. 1.11. mu. mol/L (as shown in FIG. 11), which was in turn determined by PDE-GloTMPhosphodiesterase Assay for determining the enzymatic level IC50The value is 14.64 +/-1.38 mu mol/L (as shown in figure 12), and the PDE2 enzyme inhibition effect is good.
The present invention is not limited to the above-described embodiments, and any obvious improvements, substitutions or modifications can be made by those skilled in the art without departing from the spirit of the present invention.
Claims (9)
1. A pyrimidine acetamide compound and its pharmaceutically acceptable salt have the following structure,
wherein X is NH-R1;
R1Selected from hydrogen, alkyl, aryl, heteroaryl, -C (═ O) -alkyl, -C (═ O) -aryl, or-C (═ O) -heteroaryl, any of which may optionally be substituted with one or more independent Q1Substituted by groups;
Q1selected from hydrogen, halogen, -CN, -CF3,-OCF3,-NO2Oxy, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, heterocycloaryl, -OR2,-S(O)nR3,-NR4R5,-SO2NR4R5,-C(O)R6,-C(O)NR4R5,-C(O)OR7,-OC(O)R8,-NR4C(O)R6,-NR4S(O)2R9,-NR10C(O)NR4R5,-NR10S(O)2NR4R5or-NR10S(O)NR4R5Any of the foregoing groups may optionally be substituted with one or more independent hydrogen, halogen, -CN, -OH, -NH2,-NO2Oxy, -CF3,-OCF3,-CO2H,-S(O)nH, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, heteroaryl or-O-alkyl, any of which may be partially or fully halogenated;
n is 0, 1, or 2.
2. The compound of claim 1 which is 4- {2- [5- (2-hydroxy-ethyl) -4-methyl-6-oxo-1,6-dihydro-pyrimidin-2-ylsulfanyl ] -acetylamino } -benzoic acid isopropyl ester, N- (3-ethynyl-5,6-dihydro-4H-cyclopenta [ b ] thiophen-2-yl) -2- [5- (2-hydroxy-ethyl) -4-methyl-6-oxo-1, 6-dihydropyrimidin-2-ylsulfanyl ] -acetamide, N- (4-fluorophenyl) -2- ((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide, N-benzyl-2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide, 2- ((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) -N- (4-methoxybenzyl) acetamide, N-butyl-2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) acetamide, or 2- (((5- (2-hydroxyethyl) -4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl) thio) -N- (1,3,4-thiadiazol-2-yl) acetamide.
3. A pharmaceutical composition made from a therapeutically effective amount of a compound, hydrate, pharmaceutically acceptable salt, tautomer, stereoisomer, or precursor compound thereof, according to any one of claims 1-2, and one or more pharmaceutically acceptable carriers.
4. The pharmaceutical composition of claim 3, wherein the carrier comprises a diluent, excipient, filler, binder, wetting agent, disintegrant, absorption enhancer, surfactant, adsorption carrier, lubricant, which are conventional in the pharmaceutical field.
5. The pharmaceutical composition of claim 3, wherein the dosage form of the drug is tablet, capsule, granule, pill or other conventional dosage forms which can be prepared.
6. The use of a compound according to any one of claims 1 to 2, or a pharmaceutically acceptable salt thereof, as an inhibitor of phosphodiesterase PDE2 activity by administering to a patient a therapeutically effective amount of a compound according to any one of claims 1 to 2 or a pharmaceutical composition according to claim 3.
7. The use of a compound as claimed in claim 6, introduced into the body such as muscular, intradermal, subcutaneous, intravenous, mucosal tissue by injection, spray, nasal, eye drop, osmotic, absorption, physical or chemical mediated method; or mixed or coated with other materials and introduced into body.
8. The use of a compound according to claim 6, wherein PDE2 is a central nervous system disorder.
9. The use of a compound according to claim 8, wherein the central nervous system disorder is: psychiatric disorders and conditions; anxiety disorders; movement disorders; a substance-related disorder; mood disorders; neurodegenerative disorders; pain; autistic disorder.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010771191.7A CN111995585B (en) | 2020-08-04 | 2020-08-04 | Pyrimidine acetamides and their use as inhibitors of phosphodiesterase PDE2 activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010771191.7A CN111995585B (en) | 2020-08-04 | 2020-08-04 | Pyrimidine acetamides and their use as inhibitors of phosphodiesterase PDE2 activity |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111995585A true CN111995585A (en) | 2020-11-27 |
CN111995585B CN111995585B (en) | 2022-01-25 |
Family
ID=73462730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010771191.7A Active CN111995585B (en) | 2020-08-04 | 2020-08-04 | Pyrimidine acetamides and their use as inhibitors of phosphodiesterase PDE2 activity |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111995585B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113476452A (en) * | 2021-08-06 | 2021-10-08 | 江苏理工学院 | Application of thiadiazolo pyrimidine amide compound in preparation of medicines for treating PDE2 disorder diseases |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008110891A2 (en) * | 2007-03-09 | 2008-09-18 | Orchid Research Laboratories Limited, | New heterocyclic compounds |
WO2015018534A1 (en) * | 2013-08-09 | 2015-02-12 | Grünenthal GmbH | Novel substituted condensed pyrimidine compounds |
CN105143207A (en) * | 2013-03-14 | 2015-12-09 | 达特神经科学(开曼)有限公司 | Substituted pyridine and pyrazine compounds as pde4 inhibitors |
-
2020
- 2020-08-04 CN CN202010771191.7A patent/CN111995585B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008110891A2 (en) * | 2007-03-09 | 2008-09-18 | Orchid Research Laboratories Limited, | New heterocyclic compounds |
CN105143207A (en) * | 2013-03-14 | 2015-12-09 | 达特神经科学(开曼)有限公司 | Substituted pyridine and pyrazine compounds as pde4 inhibitors |
WO2015018534A1 (en) * | 2013-08-09 | 2015-02-12 | Grünenthal GmbH | Novel substituted condensed pyrimidine compounds |
Non-Patent Citations (1)
Title |
---|
COLUMBUS,OHIO,US: "REGISTRY", 《REGISTRY[ONLINE]》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113476452A (en) * | 2021-08-06 | 2021-10-08 | 江苏理工学院 | Application of thiadiazolo pyrimidine amide compound in preparation of medicines for treating PDE2 disorder diseases |
Also Published As
Publication number | Publication date |
---|---|
CN111995585B (en) | 2022-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1871240B (en) | Pyrrolopyrimidine thion derivatives | |
CN101981036B (en) | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | |
EP2017278B1 (en) | Dihydropyrazolopyrimidinone derivative | |
EP3398950B1 (en) | Novel kinase inhibitor against wild-type egfr and mutated egfr | |
CN103649074B (en) | Be used for the treatment of the azacyclo-of the replacement of cancer | |
CN103827083B (en) | N1-cyclammonium-N5-substituted-phenyl Biguanide derivative and preparation method thereof and the pharmaceutical composition containing this derivative | |
CN101072779B (en) | 2,4 (4,6) pyrimidine derivatives | |
EP3159340B1 (en) | Bruton's tyrosine kinase inhibitor | |
CN103930425B (en) | Pteridinone derivative and the application as EGFR, BLK, FLT3 inhibitor thereof | |
EP3312180B1 (en) | Use of pteridinone derivative serving as egfr inhibitor | |
JP2005503345A (en) | Novel 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidine | |
WO2021115401A1 (en) | Fluorine-containing heterocyclic derivatives with macrocyclic structure and use thereof | |
ZA200605781B (en) | 6-amino-5-cyano-pyrimidine-4-ones used for improving perception, power of concentration, learning efficiency, and/or memory power | |
CN107667092A (en) | Formylated N Hete rocyclic derivatives as FGFR4 inhibitor | |
JP2022524456A (en) | Condensed ring pyrimidone derivative for use in the treatment of HBV infection or HBV-induced disease | |
CN113480543B (en) | 2,6, 8-polysubstituted imidazo [1,2-a ] pyrazine and synthetic method and application thereof | |
EP3661935B1 (en) | Substituted pyrazolopyrimidines useful as kinases inhibitors | |
CN111995585B (en) | Pyrimidine acetamides and their use as inhibitors of phosphodiesterase PDE2 activity | |
JPH11263789A (en) | Purine derivative and adenosine a2 receptor antagonist as agent for preventing and treating diabetes | |
CN111995563A (en) | Inhibitors of phosphodiesterase PDE2 activity | |
CN111973591A (en) | Application of phosphodiesterase PED2 activity inhibitor in preparation of drugs for treating PED2 disorder diseases | |
EP2716639A1 (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses | |
CN113476452A (en) | Application of thiadiazolo pyrimidine amide compound in preparation of medicines for treating PDE2 disorder diseases | |
CN101479278B (en) | Novel 4-amino-3-(-azolyl-phenoxymethyl)-thieno[3,2]pyridine-7-carboxylic acid derivatives | |
WO2019126141A1 (en) | Compounds and compositions for treating fibrosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20201127 Assignee: Jiangsu Dao'an Chemical Co.,Ltd. Assignor: CHANGZHOU University Contract record no.: X2023980052015 Denomination of invention: Pyrimidine acetamide compounds and their application as inhibitors of phosphodiesterase PDE2 activity Granted publication date: 20220125 License type: Common License Record date: 20231213 |